More Articles

China cuts drug prices for the second time in 2011 Policies & Legislation | Posted 23/09/2011

China has, for the second time this year, cut the price of drugs. The maximum retail price of 82 different pharmaceutical drug types has been lowered by an average 14% in a move to reduce patient’s...

The biosimilars landscape Biosimilars/Research | Posted 23/09/2011

There is obviously a market for biosimilars. This is driven by the cost savings to be made by payers and patients alike. By 2015, IMS Health (IMS) expects spending on biosimilars to exceed US$2 bil...

US President approves patent reform Policies & Legislation | Posted 23/09/2011

On 16 September 2011, US President Barack Obama signed into law a patent-reform bill that has been backed by brand-name drugmakers but opposed by generics companies.

Sanofi announces new long-term objectives Biosimilars/News | Posted 23/09/2011

At a ‘strategy and outlook’ seminar for investors held on 6 September 2011, sanofi-aventis (sanofi) CEO Mr Christopher A Viehbacher commented on the group’s outlook. The group has undergone radical...

Generics production pulled in different directions Generics/News | Posted 23/09/2011

A few months ago it was predicted that generics manufacturers were moving ahead with the development and commercialisation of better manufacturing technologies. The largest firms had now developed...

EMA comparability studies limiting biosimilar success Biosimilars/Research | Posted 16/09/2011

The EMA’s comprehensive biosimilar regulatory pathway, which includes the need for new clinical trials and comparability studies that demonstrate quality, efficacy, and safety, is a barrier for the...

Biosimilars: barriers to entry and profitability in the EU and US Biosimilars/Research | Posted 16/09/2011

The implications of the US biosimilars law and the pending patent expiries of the 12 major biological products in the EU and the US will have an impact on the profitability and viability of the bio...

US Senate approves patent reform Policies & Legislation | Posted 16/09/2011

On 8 September 2011, the US Senate passed a patent-reform bill that has been backed by brand-name drugmakers but opposed by generic companies.